Abstract 954P
Background
The combination of PD-1 blockades with antiangiogenic drugs is the main therapeutic regimen for advanced hepatocellular carcinoma (HCC). Radiotherapy has generally been used to treat HCC with improved long-term outcome. The combination of radiotherapy and other therapies is considered to be a promising treatment for HCC. The objective of this study is to investigate the feasibility and safety of radiotherapy combined with tislelizumab plus anlotinib in advanced HCC.
Methods
In this single-center, open-label, phase II clinical trial, 45 patients(pts) with previously untreated, advanced HCC, with an age ranging from 18-75 years old, and an ECOG performance status ≤ 1 were planned to be enrolled. According to mRECIST efficacy evaluation criteria, the efficacy was evaluated by enhanced CT or MRI. RTOG/EORTC criteria was used to evaluate radiation-induced liver injury. Requirements for radiotherapy planning were D95% ≥14.2-46 Gy and ≥12.5-40 Gy for GTV and CTV, respectively. The patients underwent treatment with tislelizumab (200 mg, Q3W) plus anlotinib (8 mg, Q3W), and radiotherapy until disease progression or intolerance. The primary endpoints were ORR and OS, the secondary endpoints were PFS, DCR and safty.
Results
At data cut-off date of Feb 2023, 45 pts (44 males and 1 female) were enrolled with a median age of 51.5 years (range: 26-75). Of whom, 4 pts achieved complete response, 22 pts obtained partial response, 8 pts were stable disease, illustrating an ORR of 57.8% (95%CI 42.2-72.3) and a DCR of 75.6% (95%CI 60.5-87.1). The median PFS was 7.8 months (95%CI 5.8-9.8). The rate of treatment emerged adverse events (TEAEs) on grade 1/2 were 82.2%, and grade 3/4 were 13.3% (6/45). No grade 5 or radiation-induced liver disease were observed.
Conclusions
Radiotherapy combined with tislelizumab plus anlotinib demonstrated promising efficacy and tolerable safety profile in the treatment of advanced HCC. And this study was still ongoing and further follow-up was required to obtain final survival results subsequently.
Clinical trial identification
ChiCTR2000039022.
Editorial acknowledgement
Legal entity responsible for the study
the affiliated hospital of southwest medical university.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18